The first quarter saw the first ever biosimilar approval in the United States. In addition, breast cancer patients have gained a first-line drug with a new mechanism of action. Several new treatments for hypocholesterolemia did well in clinical trials. And companies are having continued success gaining breakthrough drug designations. Dendritic cancer vaccine trial halted; peptide vaccine awaits approval.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 1Q15. Nat Biotechnol 33, 580 (2015). https://doi.org/10.1038/nbt.3261
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3261